Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Puretech Health Plc (Puretech), a subsidiary of Royalty Pharma Plc, is a biotherapeutics company that discovers, develops and commercializes drugs to treat hematological malignancies, neuropsychiatric disorders and cancer. The company's pipeline products include LYT-100 for the treatment of idiopathic pulmonary fibrosis (IPF); LYT-200 treats hematological malignancies and metastatic solid tumors; SPT-300 which targets major depressive disorder with or without anxious distress; SPT-320 for generalized anxiety disorder (GAD); SPT-348 which treats mood and other neuropsychiatric disorders; and Cobenfy targets schizophrenia. Its proprietary a voice-based artificial intelligence platform utilizes to detect the changes in health. Puretech is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
6 Tide Street, Boston, Massachusetts, 02210
Website
puretechhealth.com
Telephone
1 617 4822333
No of Employees
56
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PRTC (LON)
Revenue (2023)
$4.8M
45%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
181.4%
(2023 vs 2022)
Market Cap*
$424.5M
Net Profit Margin (2023)
XYZ
156.2%
(2023 vs 2022)
* As of and is in US$
Puretech Health Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Cobenfy |
| LYT-100: Idiopathic Pulmonary Fibrosis (IPF) | |
| LYT-200: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In August, the company introduced a new Founded Entity Celea Therapeutics. |
| 2025 | Others | In April, the company announced to be acquired by Nordic Capital Epsilon SCA, SICAV-RAIF. |
| 2024 | Financing Agreements | In April, the company along with ARCH Venture Partners, Sofinnova Investments, and Third Rock Ventures invested US$100 million in Seaport Therapeutics. |
Competitor Comparison
| Key Parameters | Puretech Health Plc | United Therapeutics Corp | Sage Therapeutics Inc | Marinus Pharmaceuticals Inc | Damora Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Silver Spring | Cambridge | Radnor | Boston |
| State/Province | Massachusetts | Maryland | Massachusetts | Pennsylvania | Massachusetts |
| No. of Employees | 56 | 1,400 | 353 | 165 | 7 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert Lyne | Chief Executive Officer; Director | Executive Board | 2025 | - |
| Sharon Barber-Lui | Chairman - Interim | Executive Board | 2025 | - |
| Michael Inbar | Chief Accounting Officer | Senior Management | - | - |
| Eric Elenko, Ph.D. | President | Senior Management | 2024 | - |
| Charles Sherwood | General Counsel | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer